Genenta Science S.p.A. reports developments spanning its biotechnology heritage and its strategic shift toward an industrial consolidation model in Italian national-security-regulated sectors. News items cover the company’s Nasdaq-traded ADSs, capital structure, operating and financial results, and governance actions tied to the expanded corporate purpose approved under Italy’s Golden Power framework.
Company updates also include the Temferon hematopoietic stem-cell gene therapy platform for solid tumors, clinical findings in glioblastoma multiforme, and efforts to evaluate collaboration opportunities for the biotechnology platform. Recent corporate news has also addressed defense, aerospace, cybersecurity, biotechnology, and biosecurity themes as Genenta evaluates and pursues industrial integrations.
On December 17, 2021, Genenta Science (Nasdaq: GNTA) announced the completion of its upsized initial public offering, raising approximately $36 million by selling 2.4 million ADSs at $11.50 each, along with 720,114 ordinary shares to existing shareholders. The offering began trading on December 15, 2021. Roth Capital Partners and Maxim Group are involved in managing the offering. Additionally, the underwriters have a 30-day option to purchase an additional 360,000 ADSs, potentially increasing the total proceeds to around $40 million.
Genenta Science announced the pricing of its upsized initial public offering (IPO) of 2.4 million American Depositary Shares (ADSs), each priced at $11.50 per share. This offering is expected to generate approximately $36 million in gross proceeds, potentially rising to $40 million if underwriters exercise their purchase option. Trading under the ticker symbol GNTA on the Nasdaq begins on December 15, 2021, with the offering closing anticipated by December 17, 2021, pending customary conditions.